トロンビン受容体相互作用を指定するドメイン
T K Vu1, V I Wheaton, D T Hung
1Cardiovascular Research Institute, University of California, San Francisco 94143-0524.
Nature
|October 17, 1991
まとめ
研究者は,トロンビンではなくエンテロキナーゼによって活性化される新しいトロンビン受容体を設計しました. この研究は,トロンビン受容体の活性化に関する重要な洞察と,トロンボシスの潜在的な新薬標的を明らかにしています.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 薬理学 薬理学とは
背景:
- トロンビンによる血小板活性化は,動脈血栓形成において極めて重要です.
- 血小板トロンビン受容体 (PAR1) は7つのトランスメブラン領域受容体である.
- トロンビンは受容体の細胞外領域を割って信号を発信する.
研究 の 目的:
- トロンビン受容体の活性化に必要な要素を調査する.
- 活性化の性質が変化した改変されたトロンビン受容体を設計する.
- トロンビンの高い afinity と potency の構造的基礎を解明する.
主な方法:
- トロンビン分裂部位をエンテロキナーゼ分裂部位に置き換えるサイト指向型変異.
- エントロキナーゼとトロンビンによる受容体活性化を測定するための機能検査.
- トロンビン結合に関与するドメインを特定するための構造分析.
主要な成果:
- 機能的なエンテロキナーゼ受容体が成功裏に作成され,タンパク質分解が活性化に十分であることを実証しました.
- エンジニアリングされた受容体は,野生型受容体のピコモラートロンビンとは異なり,ナノモラーエンテロキナーゼ濃度を必要とする.
- ヒルジンのカルボキシル尾を模倣する特定の受容体ドメインは,アニオン結合エクソサイト経由でトロンビンの強力な結合に不可欠であると特定されました.
結論:
- 受容体タンパク質分解は,トロンビン受容体活性化の唯一の決定因子です.
- トロンビン受容体相互作用のモデルが確立され,ヒルジンのようなドメインが強調されました.
- このモデルは,血栓形成症の治療のための新型トロンビン阻害剤の設計を容易にする.
関連する概念動画
00:49The Blood-brain Barrier
Overview
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:25Drug-Receptor Bonds
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
01:15Blood Transfusion
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
01:30Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...